Swiss pharma giant Novartis recalls drugs in US

Swiss pharmaceutical firm Novartis said Sunday it was recalling four different products sold over the counter in the United States over reports of a malfunction at one of its plants.

The affected drugs are Excedrin, NoDoz, Bufferin and Gas-X Prevention, Novartis Consumer Health (NCH) said in a statement.

"NCH is taking this action as a precautionary measure, because the products may contain stray tablets, capsules, or caplets from other Novartis products, or contain broken or chipped tablets," it said.

"Mixing of different products in the same bottle could result in consumers taking the incorrect product and receiving a higher or lower strength than intended or receiving an unintended ingredient.

"This could potentially result in overdose, interaction with other medications a consumer may be taking, or an allergic reaction if the consumer is allergic to the unintended ingredient," the statement said.

The group stressed however that it was not aware of among the affected products' consumers.

The plant in Lincoln, Nebraska where the products are manufactured was shut down last month and said improvements were being carried out there.

add to favorites email to friend print save as pdf

Related Stories

Novartis announces 2,000 job losses, profits up

Oct 25, 2011

Swiss pharmaceutical giant Novartis announced 2,000 job losses Tuesday, mostly in Switzerland and the United States, while reporting net profits of $3.53 billion (2.5 billion euros) for the third quarter.

Children's liquid cold, allergy medicine recalled

May 01, 2010

(AP) -- More than 40 over-the-counter infant's and children's liquid medications are being recalled in the United States and 11 other countries because they don't meet quality standards.

Buying 'legal highs' from the Internet is a risky business

May 20, 2011

Many drugs sold as 'legal highs' on the internet do not contain the ingredients they claim. Some instead contain controlled substances and are illegal to sell over the internet. These are findings of Dr. Mark Baron, who bought ...

FDA panel to vote on painkiller restrictions

Jun 30, 2009

(AP) -- Government experts are scheduled to vote on whether Nyquil and other combination cold medications should be pulled from the market to help curb deadly overdoses.

Advil or Excedrin? New model helps predict product choices

May 30, 2008

In today's world, consumers face a dizzying array of product choices. Most often, there's not just one ideal product; it depends on the individual and the context. A beer might be perfect for relaxing after work; a sports ...

Recommended for you

Boxed warnings are common in novel therapeutics

14 hours ago

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

16 hours ago

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Perampanel for epilepsy: Still no proof of added benefit

16 hours ago

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment ...

User comments